Literature DB >> 23698120

Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2.

Tania Marchbank1, Asif Mahmood, Raymond J Playford.   

Abstract

Pancreatic secretory trypsin inhibitor (PSTI) is expressed in most bladder carcinomas, where its pathophysiological relevance is unclear. Using recombinant normal sequence PSTI/tumor-associated trypsin inhibitor (TATI), a variant associated with familial pancreatitis (N34S), an active site-inactivated variant (R18/V19), and immunoneutralization and RNA interference-mediated knockdown techniques, we investigated the actions of PSTI/TATI on cell migration (wounding monolayers), collagen invasion (gel invasion assays), and proliferation (Alamar blue) on 253J, RT4, and HT1376 human bladder carcinoma cell lines. All three forms of PSTI/TATI stimulated migration twofold, and normal sequence PSTI/TATI showed synergistic promigratory effects when added with EGF. Addition of structurally unrelated soybean trypsin inhibitor had no promigratory activity. Similar results were seen using collagen invasion assays, although the active site mutated variant had no proinvasive activity, probably due to reduced Akt2 activation. PSTI/TATI did not stimulate proliferation despite acting, at least partially, through the EGF receptor, as effects of PSTI/TATI were truncated by the addition of an EGF receptor blocking antibody or the tyrosine kinase inhibitor tyrphostin. Cell lines produced endogenous PSTI/TATI, and PSTI/TATI RNA interference knockdown or the addition of PSTI/TATI, EGF receptor, or tyrphostin blocking agents reduced migration and invasion below baseline. PSTI/TATI induced phosphorylation of the EGF receptor, ERK1 and ERK2, Akt2 and Akt3, JNK1, MKK3, and ribosomal protein S6 kinase 1. This profile was more limited than that induced by EGF and did not include Akt1, probably explaining the lack of proproliferative activity. Our findings of autocrine stimulation and synergistic responses between EGF and PSTI/TATI at concentrations found in urine and tissue suggest that PSTI/TATI has pathophysiological relevance.

Entities:  

Keywords:  cellular invasion; repair; restitution; tumor-associated trypsin inhibitor

Mesh:

Substances:

Year:  2013        PMID: 23698120     DOI: 10.1152/ajprenal.00357.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

1.  Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.

Authors:  Felix H Shek; Ruibang Luo; Brian Y H Lam; Wing Kin Sung; Tak-Wah Lam; John M Luk; Ming Sum Leung; Kin Tak Chan; Hector K Wang; Chung Man Chan; Ronnie T Poon; Nikki P Lee
Journal:  Cell Oncol (Dordr)       Date:  2017-06-19       Impact factor: 6.730

2.  Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.

Authors:  Yi-Ting Chen; Shu-Chuan Tsao; Shyng-Shiou F Yuan; Hung-Pei Tsai; Chee-Yin Chai
Journal:  Pathol Oncol Res       Date:  2015-06-03       Impact factor: 3.201

3.  The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line.

Authors:  Jing Zhang; Dongmei Wang; Na Hu; Qian Wang; Shanice Yu; Jun Wang
Journal:  Tumour Biol       Date:  2015-11-19

Review 4.  Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration.

Authors:  Joseph Shay; Hosam A Elbaz; Icksoo Lee; Steven P Zielske; Moh H Malek; Maik Hüttemann
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

5.  Pancreatic secretory trypsin inhibitor reduces multi-organ injury caused by gut ischemia/reperfusion in mice.

Authors:  Raymond J Playford; Tania Marchbank
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

Review 6.  SPINKs in Tumors: Potential Therapeutic Targets.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Minglin Zhang; Jie Chen; Xiaolan Li; Linlin Xiao; Jiajia Wang; Qian Long; Jianguo Liu; Xiaoyan Guan
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

7.  Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance.

Authors:  Fei Chen; Qilai Long; Da Fu; Dexiang Zhu; Yan Ji; Liu Han; Boyi Zhang; Qixia Xu; Bingjie Liu; Yan Li; Shanshan Wu; Chen Yang; Min Qian; Jianmin Xu; Suling Liu; Liu Cao; Y Eugene Chin; Eric W-F Lam; Jean-Philippe Coppé; Yu Sun
Journal:  Nat Commun       Date:  2018-10-17       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.